Alves Paula Melo, Azevedo Maria Teresa, Ferreira Fernando, Tastekin Ebru, Canberk Sule, Schmitt Fernando C
Pathology and Molecular Genetics, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
Polytechnic Institute of Health of the North (IPSN), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), 4585-116 Paredes, Portugal.
Diagnostics (Basel). 2024 May 22;14(11):1074. doi: 10.3390/diagnostics14111074.
Serous effusion cytology is a pivotal diagnostic and staging tool in clinical pathology, valued for its simplicity and cost-effectiveness. Staining techniques such as Giemsa and Papanicolaou are foundational, yet the search for rapid and efficient alternatives continues. Our study assesses the efficacy of an in-house-developed BlueStain, a toluidine blue variant, within the International System for Reporting Serous Fluid Cytopathology (TIS), aiming to optimize diagnostic clarity and resource use.
This section provides details on the cohort of 237 patients with serous effusions, the ethical approval process, sample collection, and staining procedures with BlueStain, Papanicolaou, and Giemsa. It also describes the microscopic evaluation criteria, scoring system, and statistical methods used to compare the stains.
BlueStain demonstrated notable performance, particularly in identifying malignant cells, presenting a competitive alternative to the Papanicolaou stain, which, despite higher quality indices in other categories, requires more resources and time. The study revealed that BlueStain might offer a valuable balance between quality and efficiency, especially in cases where rapid diagnostic turnaround is essential.
Our findings suggest that BlueStain is a viable staining method in the context of serous effusions, capable of providing detailed cytomorphological analysis. While traditional stains hold their place for their established diagnostic clarity, BlueStain offers a rapid and resource-optimized alternative. The absence of definitive diagnostic criteria in the atypical category and the inherent sample heterogeneity underscores the necessity for adaptable staining methods like BlueStain. The study highlights the potential trade-offs between detail and practicality in staining techniques, advocating for further research into innovative methods that do not compromise diagnostic precision for cost and time efficiency.
浆液性积液细胞学检查是临床病理学中一种关键的诊断和分期工具，因其操作简单且成本效益高而受到重视。吉姆萨染色和巴氏染色等染色技术是基础，但人们仍在不断寻找快速有效的替代方法。我们的研究评估了自行研发的蓝染剂（一种甲苯胺蓝变体）在国际浆液性液体细胞病理学报告系统（TIS）中的效果，旨在优化诊断清晰度和资源利用。
本节详细介绍了237例浆液性积液患者的队列、伦理审批过程、样本采集以及使用蓝染剂、巴氏染色和吉姆萨染色的染色程序。还描述了用于比较染色剂的显微镜评估标准、评分系统和统计方法。
蓝染剂表现出显著性能，尤其是在识别恶性细胞方面，是巴氏染色的一种有竞争力的替代方法。巴氏染色尽管在其他类别中有更高的质量指标，但需要更多资源和时间。研究表明，蓝染剂可能在质量和效率之间提供有价值的平衡，特别是在快速诊断周转至关重要的情况下。
我们的研究结果表明，蓝染剂在浆液性积液的情况下是一种可行的染色方法，能够提供详细的细胞形态学分析。虽然传统染色因其既定的诊断清晰度而占有一席之地，但蓝染剂提供了一种快速且资源优化的替代方法。非典型类别中缺乏明确的诊断标准以及样本固有的异质性凸显了像蓝染剂这样的适应性染色方法的必要性。该研究强调了染色技术在细节和实用性之间的潜在权衡，主张进一步研究不牺牲诊断精度以换取成本和时间效率的创新方法。
